Soares-da-Silva P - Search Results

1

Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers.

Milovan D, Almeida L, Romach MK, Nunes T, Rocha JF, Sokowloska M, Sellers EM, Soares-da-Silva P. Milovan D, et al. Epilepsy Behav. 2010 Aug;18(4):366-73. doi: 10.1016/j.yebeh.2010.04.022. Epub 2010 Jun 18. Epilepsy Behav. 2010. PMID: 20708576 Clinical Trial.

2

Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans.

Almeida L, Soares-da-Silva P. Almeida L, et al. Drugs R D. 2003;4(4):207-17. doi: 10.2165/00126839-200304040-00001. Drugs R D. 2003. PMID: 12848585 Clinical Trial.

3

Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans.

Almeida L, Soares-da-Silva P. Almeida L, et al. Drugs R D. 2003;4(5):269-84. doi: 10.2165/00126839-200304050-00001. Drugs R D. 2003. PMID: 12952496 Clinical Trial.

4

Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.

Silveira P, Vaz-da-Silva M, Almeida L, Maia J, Falcão A, Loureiro A, Torrão L, Machado R, Wright L, Soares-da-Silva P. Silveira P, et al. Eur J Clin Pharmacol. 2003 Nov;59(8-9):603-9. doi: 10.1007/s00228-003-0680-5. Epub 2003 Sep 27. Eur J Clin Pharmacol. 2003. PMID: 14517707 Clinical Trial.

5

Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects.

Almeida L, Soares-da-Silva P. Almeida L, et al. J Clin Pharmacol. 2003 Dec;43(12):1350-60. doi: 10.1177/0091270003258666. J Clin Pharmacol. 2003. PMID: 14615471 Clinical Trial.

6

Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa.

Almeida L, Vaz-da-Silva M, Silveira P, Falcão A, Maia J, Loureiro A, Torrão L, Machado R, Wright L, Soares-da-Silva P. Almeida L, et al. Clin Neuropharmacol. 2004 Jan-Feb;27(1):17-24. doi: 10.1097/00002826-200401000-00007. Clin Neuropharmacol. 2004. PMID: 15090932 Clinical Trial.

7

Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.

Almeida L, Soares-da-Silva P. Almeida L, et al. J Clin Pharmacol. 2004 Aug;44(8):906-18. doi: 10.1177/0091270004267591. J Clin Pharmacol. 2004. PMID: 15286095 Clinical Trial.

8

Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093).

Maia J, Vaz-da-Silva M, Almeida L, Falcão A, Silveira P, Guimarães S, Graziela P, Soares-da-Silva P. Maia J, et al. Drugs R D. 2005;6(4):201-6. doi: 10.2165/00126839-200506040-00002. Drugs R D. 2005. PMID: 15991880 Clinical Trial.

9

Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects.

Almeida L, Falcão A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. Almeida L, et al. J Clin Pharmacol. 2005 Sep;45(9):1062-6. doi: 10.1177/0091270005279364. J Clin Pharmacol. 2005. PMID: 16100301 Clinical Trial. No abstract available.

10

Eslicarbazepine acetate (BIA 2-093) : relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulations.

Fontes-Ribeiro C, Nunes T, Falcão A, Neta C, Lima R, Tavares S, Almeida L, Macedo T, Soares-da-Silva P. Fontes-Ribeiro C, et al. Drugs R D. 2005;6(5):253-60. doi: 10.2165/00126839-200506050-00001. Drugs R D. 2005. PMID: 16128595 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

438 results

Search Page

Filters